Cancer Vaccines 2025, Part I: The mRNA Revolution

The race to develop cancer vaccines is accelerating. Fueled by decades of research, mRNA platforms have emerged as a leading modality in oncology, delivering early clinical signals across multiple tumor types.

This article kicks off our multi-part series on the evolving landscape of cancer vaccines.
We begin with therapeutic mRNA vaccines, the most clinically advanced platform to date. In the coming weeks, we’ll explore other key approaches driving the field forward, including DNA-based platforms, peptide/protein vaccines, viral vectors, and cell-based strategies.

Each article will unpack not only the science but also the strategic implications for biopharma, investors, and clinical innovators shaping the future of cancer treatment.

How mRNA Cancer Vaccines Work?

mRNA (messenger RNA) vaccines deliver genetic instructions that teach the body’s own cells to produce tumor antigens, unique proteins found on cancer cells. These antigens are then displayed on the cell surface and recognized by the immune system, especially T cells.

The mRNA is packaged in lipid nanoparticles (LNPs) for protection and delivery. Once injected, the mRNA enters antigen-presenting cells (APCs), which process the tumor antigens and activate CD8⁺ cytotoxic T cells (which kill cancer cells) and CD4⁺ helper T cells (which support the immune response). This triggers a targeted immune attack against cancer.

Unlike traditional vaccines, mRNA doesn’t enter the cell’s nucleus or alter DNA. It’s transient, safe, and highly adaptable — ideal for fast design against cancer-specific targets.

Types of mRNA Cancer Vaccines: Personalized, Off-the-Shelf, and Hybrid Models

Therapeutic mRNA cancer vaccines fall into three major categories, differing in their degree of personalization, production complexity, and clinical applicability:

Personalized Vaccines

Fully customized for each patient. After surgical removal or biopsy, the tumor is sequenced to identify neoantigens — unique mutations present only in cancer cells. These are encoded into a tailored mRNA construct designed specifically for that individual.

• Pros: Maximal specificity, tailored immune response.
• Cons: Expensive, time-consuming (4–6 weeks), complex logistics.

Off-the-Shelf Vaccines

Use fixed sets of tumor-associated antigens common to many patients. These vaccines are mass-produced and ready for administration without patient-specific customization.

• Pros: Fast, scalable, cost-effective.
• Cons: Less personalized, may not match a patient’s tumor profile.

Semi-Personalized (Hybrid) Vaccines

A middle-ground strategy. These vaccines target shared driver mutations (like KRAS, TP53, IDH1) found in genetically defined subgroups. They are pre-manufactured but only administered to patients whose tumors carry the relevant mutation.

• Pros: Faster than personalized vaccines; more biologically targeted than generic ones.
• Cons: Limited to mutation-positive patients; requires screening.

Comparative Table: Types of mRNA Cancer Vaccines

Feature	Personalized	Off-the-Shelf	Semi-Personalized (Hybrid)
Customization	Fully individualized per patient	Same for all patients	For subgroups with shared mutations
Production Time	4–6 weeks per dose	Ready-made	Pre-made, mutation-specific
Scalability	Low (complex logistics)	High (mass-produced)	Medium
Target Specificity	Very high	Moderate	High in selected patients
Cost	High	Lower	Medium

Checkpoint Inhibitor Combinations: Why They Matter

Most clinical trials involving mRNA cancer vaccines now include a checkpoint inhibitor (typically anti-PD-1 or anti-PD-L1). Why? Because these combinations are synergistic. While mRNA vaccines bring new tumor-specific T cells into the fight, checkpoint inhibitors remove the immune system’s brakes, allowing T cells to function effectively within the tumor microenvironment.

Top mRNA Cancer Vaccine Trials in 2025

Therapeutic mRNA vaccines are advancing rapidly across multiple tumor types, with several studies demonstrating early clinical impact. Below is a concise overview of leading trials by indication.

Melanoma

• Moderna + Merck (KEYNOTE-942): In a phase 2b trial, personalized mRNA-4157 (V940) + pembrolizumab reduced post-resection recurrence by 44% and distant metastasis risk by 65% compared to anti-PD-1 alone.
• BioNTech (BNT111): Off-the-shelf vaccine targeting four melanoma antigens; achieved 18% ORR in PD-1-refractory patients.

 Non-Small Cell Lung Cancer (NSCLC)

• Moderna + Merck: Phase III trial (The INTerpath-009) is ongoing in 868 patients post-chemotherapy. V940 vaccine is administered with pembrolizumab every 3 weeks for up to 9 doses.

 Pancreatic Cancer

• BioNTech (Autogene cevumeran): In phase 1 study early antitumor activity was observed, including complete responses, even in heavily pretreated patients. These findings support advancing it into earlier-line trials where immune responsiveness is higher.

Head & Neck Squamous Cell Carcinoma (HNSCC)

• BioNTech (BNT113): For HPV16+ tumors; early data show 47% response with pembrolizumab.
• Transgene (TG4050): Viral vector-based mRNA vaccine targeting neoantigens. In a small trial, no recurrences were observed over 18 months.

Glioblastoma

• CureVac (CVGBM): Unmodified mRNA vaccine induced de novo T-cell responses in 77% of patients.

Emerging and Early-Stage Trials

• Generic mRNA Immune Activator (Nature Biomedical Engineering, 2024): A “universal” vaccine designed to trigger broad immune activation rather than targeting specific neoantigens. Still preclinical but offers potential cross-tumor utility.
• UK NHS Colorectal Cancer Trial (May 2024): A personalized mRNA vaccine study launched by the UK National Health Service, currently in recruitment phase.

Key Challenges Facing mRNA Cancer Vaccines in 2025+

Despite remarkable momentum, therapeutic mRNA vaccines still face five core challenges:

• Manufacturing Bottlenecks

Personalized vaccines require tumor sequencing → neoantigen prediction → rapid mRNA synthesis — all under tight timelines. Scaling this workflow is still a logistical feat.

• High Costs & Access

Current production costs are steep — reaching ~$100–300k per patient. Reimbursement and equitable access remain major open questions.

Cost vs. Time Trade-offs in mRNA Cancer Vaccine Platforms

Platform Type	Production Time	Estimated Cost per Patient	Notes
Personalized (e.g., V940)	~30–45 days	~$100K–300K	Highest precision, slowest and costliest
Off-the-Shelf (e.g., BNT111)	~2–5 days	~$10K–30K	Fastest, scalable, limited specificity
Semi-Personalized (e.g., SLATE)	~10–20 days	~$50K–80K	Balances speed and targeting

• Cold Tumors & Immune Evasion

Tumors like glioblastoma or pancreatic cancer lack immune infiltration or suppress T cells. Vaccine response may be blunted without combo strategies.

• Timing & MRD Targeting

Vaccines show best results post-surgery, when minimal residual disease is present. This demands tight integration with ctDNA diagnostics.

• Regulatory Complexity

How do you approve a drug made uniquely for each patient? New regulatory pathways are emerging, but frameworks are still evolving.

Bottom line: mRNA vaccines have game-changing potential — but unlocking it will require innovation not just in biology, but in infrastructure, policy, and delivery.

Pipeline Momentum and What to Watch (2025–2027)

Therapeutic mRNA cancer vaccines are transitioning from experimental pipelines to the commercial frontier. Over the next three years, key clinical milestones and growing investor interest are expected to reshape the oncology landscape.

Market Forecast

• The global market for mRNA cancer vaccines is projected to exceed $5–7 billion by 2030, with compound annual growth rates (CAGR) surpassing 30% starting in 2025.
• The first regulatory approvals are anticipated by late 2026 to 2027, contingent on pivotal Phase III readouts (e.g., Moderna’s V940 for melanoma and NSCLC).
• Personalized vaccines may command premium prices (~$100K–300K/patient), but cost-effectiveness could be justified in adjuvant settings where relapse risk is high.

 Key Growth Drivers

• Checkpoint combo synergy: Strong biological rationale and data are driving rapid expansion of trials combining mRNA vaccines with anti-PD-1/L1 agents.
• Early-stage disease targeting: Focus is shifting from metastatic to adjuvant and MRD settings, where immune responses may be more effective.
• Scalability and tech transfer: Advances in manufacturing and AI-guided neoantigen prediction may reduce turnaround time and broaden access by 2026–27

From Promise to Practice — The mRNA Oncology Shift Is Underway

mRNA cancer vaccines have crossed the boundary from theoretical innovation to clinical momentum. What began as an emergency platform during the COVID-19 pandemic is now defining a new frontier in oncology and one that is faster, more adaptive, and increasingly personalized.

By 2027, we may see the first approvals in melanoma and lung cancer, setting not only therapeutic precedents but also shaping new regulatory and reimbursement frameworks. For sponsors, this moment demands agility: whether through internal development, strategic licensing, or partnerships with global CROs.

At Cromos Pharma, we are closely tracking these breakthroughs and helping biopharma teams bring mRNA platforms from bench to bedside across key oncology hubs. As the cancer vaccine race accelerates, execution will separate leaders from followers. Now is the time to move.